Comparison 2. Switching ‐ new antipsychotic regimen vs continuation on previous regimen: 1b. new atypical from olanzapine ‐ medium term (3‐12 months).

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Weight: 1. Body weight (kg)	2	287	Mean Difference (IV, Fixed, 95% CI)	‐1.94 [‐3.97, 0.08]
1.1 switching to aripiprazole	1	158	Mean Difference (IV, Fixed, 95% CI)	‐3.21 [‐9.03, 2.61]
1.2 switching to quetiapine	1	129	Mean Difference (IV, Fixed, 95% CI)	‐1.77 [‐3.93, 0.39]
2 Weight: 2a. BMI ‐ increase	1	173	Risk Ratio (M‐H, Fixed, 95% CI)	0.28 [0.13, 0.57]
3 Weight: 2b. BMI ‐ average change	1	129	Mean Difference (IV, Fixed, 95% CI)	‐0.52 [‐1.26, 0.22]
3.1 switching to quetiapine	1	129	Mean Difference (IV, Fixed, 95% CI)	‐0.52 [‐1.26, 0.22]
4 Waist circumference ‐ increase	1	173	Risk Ratio (M‐H, Fixed, 95% CI)	0.92 [0.76, 1.11]
5 Physiological measures: 1a. Average changes ‐ switching to quetiapine	1		Mean Difference (IV, Fixed, 95% CI)	Subtotals only
5.1 lipids ‐ cholesterol levels	1	130	Mean Difference (IV, Fixed, 95% CI)	0.02 [‐0.23, 0.27]
5.2 lipids ‐ low density lipoproteins	1	130	Mean Difference (IV, Fixed, 95% CI)	‐0.02 [‐0.24, 0.20]
5.3 lipids ‐ high density lipoproteins	1	130	Mean Difference (IV, Fixed, 95% CI)	0.03 [‐0.05, 0.11]
5.4 lipids ‐ triglyceride	1	130	Mean Difference (IV, Fixed, 95% CI)	0.13 [‐0.18, 0.44]
6 Physiological measures: 1b. Percentage changes ‐ switching to aripiprazole			Other data	No numeric data
6.1 lipids ‐ cholesterol			Other data	No numeric data
6.2 lipids ‐ triglycerides			Other data	No numeric data
6.3 lipids ‐ low density lipoproteins			Other data	No numeric data
6.4 lipids ‐ high density lipoproteins			Other data	No numeric data
7 Physiological measures: 1c. Average changes ‐ sugar	2		Mean Difference (IV, Random, 95% CI)	Subtotals only
7.1 fasting insulin level	1	155	Mean Difference (IV, Random, 95% CI)	‐0.3 [‐4.04, 3.44]
7.2 insulin level	1	125	Mean Difference (IV, Random, 95% CI)	8.63 [‐8.82, 26.08]
7.3 c‐peptides	1	153	Mean Difference (IV, Random, 95% CI)	0.36 [‐0.19, 0.91]
7.4 sugar ‐ fasting glucose ‐ switching to aripiprazole and quetiapine	2	280	Mean Difference (IV, Random, 95% CI)	‐2.53 [‐2.94, ‐2.11]
8 Global state: 1a. Relapse	1	133	Risk Ratio (M‐H, Fixed, 95% CI)	1.31 [0.55, 3.11]
9 Global state: 1b. Average change (CGI‐S, high decline = good) ‐ switching to aripiprazole	1	164	Mean Difference (IV, Fixed, 95% CI)	0.29 [‐0.01, 0.59]
10 Mental state: Average change (PANSS, high decline = good) ‐ switching to quetiapine	1	133	Mean Difference (IV, Fixed, 95% CI)	‐3.63 [‐10.31, 3.05]
11 Loss to follow‐up	2	306	Risk Ratio (M‐H, Random, 95% CI)	1.67 [1.22, 2.28]
11.1 switching to aripiprazole	1	173	Risk Ratio (M‐H, Random, 95% CI)	1.40 [0.89, 2.21]
11.2 switching to quetiapine	1	133	Risk Ratio (M‐H, Random, 95% CI)	1.94 [1.27, 2.96]
12 Adverse events: 1. Serious adverse event	2	305	Risk Ratio (M‐H, Fixed, 95% CI)	0.99 [0.48, 2.07]
12.1 switching to aripiprazole	1	172	Risk Ratio (M‐H, Fixed, 95% CI)	0.64 [0.24, 1.71]
12.2 switching to quetiapine	1	133	Risk Ratio (M‐H, Fixed, 95% CI)	1.83 [0.56, 5.96]
13 Adverse events: 2. Treatment emergent adverse events	2	302	Risk Ratio (M‐H, Fixed, 95% CI)	1.07 [0.92, 1.24]
13.1 switching to aripiprazole	1	172	Risk Ratio (M‐H, Fixed, 95% CI)	1.19 [0.92, 1.53]
13.2 switching to quetiapine	1	130	Risk Ratio (M‐H, Fixed, 95% CI)	0.97 [0.82, 1.14]